AGFG2

Across TCGA pan-cancer cohorts, AGFG2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AGFG2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AGFG2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AGFG2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where AGFG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.630	0.287	<.001	68	view →
COAD	DFS	Median	All	1.000	0.889	.023	54	view →
CCRCC	OS	Quartile	III,IV	0.808	0.343	.009	23	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	2	view →
LUAD	OS	Quartile	III,IV	0.848	0.415	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AGFG2–PDAC (DFS)

Open the PDAC breakdown →